These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35696229)

  • 1. New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.
    Yu WJ; Cottler L; Li JH
    J Food Drug Anal; 2021 Mar; 29(1):168-181. PubMed ID: 35696229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New psychoactive substances in Taiwan: challenges and strategies.
    Feng LY; Li JH
    Curr Opin Psychiatry; 2020 Jul; 33(4):306-311. PubMed ID: 32167950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergency department visits due to new psychoactive substances and other illicit drugs in Taiwan: preliminary results of the Taiwan Emergency Department Drug Abuse Surveillance (TEDAS) project.
    Lin CC; Weng TI; Ng CJ; Shih CP; Hsu J; Liao YC; Yang CC; Fang CC;
    Clin Toxicol (Phila); 2022 Jun; 60(6):708-715. PubMed ID: 35315299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of cathinones and other new psychoactive substances in hair of parents and children of families with known or suspected parental abuse of conventional illegal drugs.
    Niebel A; Pragst F; Krumbiegel F; Hartwig S
    Forensic Sci Int; 2022 Feb; 331():111148. PubMed ID: 34923263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
    Feng LY; Wada K; Chung H; Han E; Li JH
    Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of illegal drug use pattern in Taiwan and Korea from 2006 to 2014.
    Feng LY; Yu WJ; Chang WT; Han E; Chung H; Li JH
    Subst Abuse Treat Prev Policy; 2016 Sep; 11(1):34. PubMed ID: 27663984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of synthetic substances in France and in Europe].
    Debruyne D; Monzon E; Perino J; Haramburu F; Daveluy A; Lazès-Charmetant A; Giraudon I
    Therapie; 2021; 76(3):221-228. PubMed ID: 32859404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between users' and addiction medicine experts' harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates.
    Bonnet U; Specka M; Kanti AK; Scherbaum N
    Front Psychiatry; 2022; 13():1041762. PubMed ID: 36465301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wastewater-based epidemiology to monitor 68 NPS/conventional drug use in Taipei metropolitan area in Taiwan during and after COVID-19 pandemic.
    Ting TT; Chen PC; Chang YC; Chiang PJ; Li HC; Chen SH; Chen PC; Chu HT; Chuang PY; Liu YH; Chen PS
    J Hazard Mater; 2024 Sep; 476():135020. PubMed ID: 38959832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs.
    Rousis N; Bade R; Romero-Sánchez I; Mueller JF; Thomaidis NS; Thomas KV; Gracia-Lor E
    Environ Int; 2023 Aug; 178():108075. PubMed ID: 37399770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
    Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.
    Palamar JJ; Acosta P; Sherman S; Ompad DC; Cleland CM
    Am J Drug Alcohol Abuse; 2016 Nov; 42(6):624-632. PubMed ID: 27315522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 16. Scheduling of new psychoactive substance the Swiss way: A review and critical analysis.
    Grafinger KE; Bernhard W; Weinmann W
    Sci Justice; 2019 Jul; 59(4):459-466. PubMed ID: 31256819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring psychoactive substance use at six European festivals through wastewater and pooled urine analysis.
    Bijlsma L; Celma A; Castiglioni S; Salgueiro-González N; Bou-Iserte L; Baz-Lomba JA; Reid MJ; Dias MJ; Lopes A; Matias J; Pastor-Alcañiz L; Radonić J; Turk Sekulic M; Shine T; van Nuijs ALN; Hernandez F; Zuccato E
    Sci Total Environ; 2020 Jul; 725():138376. PubMed ID: 32298891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances.
    Fernández-Calderón F; Cleland CM; Palamar JJ
    Addict Behav; 2018 Mar; 78():85-93. PubMed ID: 29128711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries.
    Kurcevič E; Lines R
    Harm Reduct J; 2020 Nov; 17(1):94. PubMed ID: 33256747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical challenges of synthetic cathinones.
    Schifano F; Napoletano F; Arillotta D; Zangani C; Gilgar L; Guirguis A; Corkery JM; Vento A
    Br J Clin Pharmacol; 2020 Mar; 86(3):410-419. PubMed ID: 31674690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.